The efficacy of carvedilol in improving cardiac function and survival in patients with anthracycline-induced cardiotoxicity: a comprehensive systematic review and meta-analysis.

Int J Cardiol Heart Vasc · 2026 · PMC12818984 · PMID 41567130

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

By carvedilol dose When studies were stratified according to carvedilol dosage, six studies using 12.5 mg/day showed a trend favoring carvedilol ( SMD = −0.24 [95 % CI: −0.54, 0.05], I 2 = 59 % ), whereas studies using > 12.5 mg/day also favored carvedilol ( SMD = –0.18 [95 % CI: −0.50, 0.14], I 2 = 46 % ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.